Cargando…
Cancer immunotherapy in routine cost‐effective cancer care?
Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable approach in ge...
Autor principal: | Feldmann, Sir Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220302/ https://www.ncbi.nlm.nih.gov/pubmed/30322840 http://dx.doi.org/10.15252/emmm.201809660 |
Ejemplares similares
-
Live vaccines—a short‐cut to cancer viro‐immunotherapy
por: Wirth, Thomas C, et al.
Publicado: (2019) -
Miniature integrated spectrometers towards high-performance and cost-effective
por: Sun, Haoxuan, et al.
Publicado: (2023) -
Counting the neurological cost of COVID-19
por: Baig, Abdul Mannan
Publicado: (2021) -
After surviving cancer, what about late life effects of the cure?
por: Nonnekens, Julie, et al.
Publicado: (2016) -
Should We Invest in Martian Brine Research to Reduce Mars Exploration Costs?
por: Martín-Torres, Javier, et al.
Publicado: (2017)